US 12,083,183 B2
Conjugate of biotin-modified dimer and phthalocyanine dye
Motomu Kanai, Tokyo (JP); Kenzo Yamatsugu, Tokyo (JP); Toshifumi Tatsumi, Tokyo (JP); Kazuki Takahashi, Tokyo (JP); Tatsuhiko Kodama, Tokyo (JP); Akira Sugiyama, Tokyo (JP); Takefumi Yamashita, Tokyo (JP); Masanobu Tsukagoshi, Tokyo (JP); Yuzo Toda, Tokyo (JP); and Junji Nishigaki, Tokyo (JP)
Assigned to THE UNIVERSITY OF TOKYO, Tokyo (JP); and SAVID THERAPEUTICS INC., Tokyo (JP)
Filed by THE UNIVERSITY OF TOKYO, Tokyo (JP); and SAVID THERAPEUTICS INC., Tokyo (JP)
Filed on Apr. 22, 2021, as Appl. No. 17/237,709.
Prior Publication US 2023/0106135 A1, Apr. 6, 2023
Int. Cl. A61K 47/64 (2017.01); A61K 31/4188 (2006.01); A61K 47/68 (2017.01)
CPC A61K 47/64 (2017.08) [A61K 31/4188 (2013.01); A61K 47/6803 (2017.08)] 20 Claims
 
1. A complex comprising (a) a compound represented by the following formula (1) or a salt thereof:

OG Complex Work Unit Chemistry
wherein
X represents a substituent having a hydrophilic group, a cationic group or an amino group at the terminus thereof, or —OH,
X1a, X1b, X2a and X2b each independently represent O or NH,
Y1 and Y2 each independently represent C or S,
Z1 and Z2 each independently represent O, S or NH,
V1 and V2 each independently represent S or S+—O−,
n1 and n2 each independently represent an integer of 0 or 1,
L1 and L2 each independently represent a divalent linking group,
L3 represents a trivalent linking group,
L4, L5, and L6 each independently represent a divalent linking group, and (b) a conjugate of mutant streptavidin, comprising a molecular probe conjugated to mutant streptavidin.